C3.ai stock fell amid a massive rout in artificial intelligence stocks earlier in the week. Is C3.ai stock a sell now? Shares ...

C3.ai Inc. closed 30.46% below its 52-week high of $45.08, which the company achieved on December 10th.

Investors should be on high alert for more AI-stock weakness after DeepSeek disrupted markets and sent shares tumbling.

Wall Street shocked by DeepSeek AI's low-cost, high-performance model using reduced-capacity Nvidia GPUs. Competitors take a hit, but potential for innovation and affordability in AI technology.

The launch of DeepSeek had made investors question whether to allocate capital to higher-cost AI-related companies like Nvidia.

OpenAI launched its cost-efficient o3-mini model in the same week that DeepSeek's R1 disrupted the tech industry.

KBC Group NV grew its holdings in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 3,862.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange ...

Royal Bank of Canada reiterated their sector perform rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) in a report released on Wednesday,Benzinga reports. Royal Bank of Canada ...

Traders work on the floor at the New York Stock Exchange (NYSE) in New York City, U.S., December 10, 2024. REUTERS/Brendan McDermid/File Photo U.S. stocks ended lower on Friday, with indexes ...

Reliable exposure to long-term corporate bonds. Our research team assigns Silver ratings to strategies that they have a high conviction will outperform the relevant index, or most peers, over a ...

Recent market conditions provided tailwinds to some of the portfolio’s exposures, but long-term performance can be vulnerable to market selloffs. This approach merits an Average Process rating.